Items where authors include "Walls, G."

Article

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Punjabi, A., Barrett, E., Cheng, A. et al. (21 more authors) (2021) Neutrophil–lymphocyte ratio and absolute lymphocyte count as prognostic markers in patients treated with curative-intent radiotherapy for non-small cell lung cancer. Clinical Oncology, 33 (8). e331-e338. ISSN 0936-6555

Evison, M., Barrett, E., Cheng, A. et al. (20 more authors) (2021) Predicting the risk of disease recurrence and death following curative-intent radiotherapy for non-small cell lung cancer: The development and validation of two scoring systems from a large multicentre UK cohort. Clinical Oncology, 33 (3). pp. 145-154. ISSN 0936-6555

Conference or Workshop Item

Horne, A., Ali, A., Brown, S. et al. (28 more authors) (2022) 153 CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). In: 20th Annual British Thoracic Oncology Group Conference 2022, 27-28 Jan 2022, Virtual.

Proceedings Paper

Walls, G., Horne, A., Harrow, S. et al. (17 more authors) (2025) 3513: ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: interim report from the CONCORDE phase Ib trial (NCT04550104). In: Radiotherapy and Oncology. ESTRO 2025, 02-06 May 2025, Vienna, Austria. , s1395-s1397.

Horne, A., Walls, G., Brown, S. et al. (17 more authors) (2025) An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRIs) in combination with conventional radiotherapy in NSCLC. In: Journal of Thoracic Oncology. European Lung Cancer Congress 2025, 26-29 Mar 2025, Paris, France. Elsevier BV , S150.

Walls, G., Horne, A., Franks, K. et al. (23 more authors) (2025) 255 An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRis) in combination with conventional radiotherapy in NSCLC. In: Lung Cancer. 23rd BTOG Annual Conference 2025, 03-05 Mar 2025, Belfast, Northern Ireland. Elsevier BV , p. 108364.